European Myeloma Network Meeting - 3rd Meeting European Myeloma Network Virtual Meeting March 3-4-5-6, 2021 - Studio ER Congressi
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
European Myeloma Network Virtual Meeting
March 3-4-5-6, 2021
3rd Meeting
European Myeloma European Myeloma Network Virtual Meeting
March 3-4-5-6, 2021
Network Meeting
European Myeloma Network Virtual Meeting
March 3-4-5-6, 2021
3 rd Meeting
European Myeloma Network Meeting
FACULTY
Hervé Avet-Loiseau Toulouse, France Monique C. Minnema Utrecht, The Netherlands
Meral Beksac Ankara, Turkey Philippe Moreau Nantes, France
Mario Boccadoro Turin, Italy Kate Morgan Edinburgh, United Kingdom
Niccolò Bolli Milan, Italy Nikhil C. Munshi Boston, USA
Annemiek Broijl Rotterdam, The Netherlands Enrique M. Ocio Santander, Spain
Michele Cavo Bologna, Italy Stefania Oliva Turin, Italy
Gordon Cook Leeds, United Kingdom Bruno Paiva Pamplona, Spain
Thomas Cupedo Rotterdam, The Netherlands Giovanni Palladini Pavia, Italy
Mattia D’Agostino Turin, Italy Charlotte Pawlyn London, United Kingdom
Michel Delforge Leuven, Belgium Noemi Puig Salamanca, Spain
Meletios A. Dimopoulos Athens, Greece Marc Raab Heidelberg, Germany
Isabelle Durand-Zaleski Paris, France Jakub Radocha Hradec Kralove, Czechia
Brian G.M. Durie North Hollywood, USA Noopur Raje Boston, USA
Hermann Einsele Würzburg, Germany Karthik Ramasamy Oxford, United Kingdom
Thierry Facon Lille, France Leo Rasche Würzburg, Germany
Carlos Fernández de Larrea Barcelona, Spain Paula Rodriguez Otero Pamplona, Spagna
Jaime Gallego Navarra, Spain Jesus San-Miguel Navarra, Spain
Francesca Gay Turin, Italy Hans Scheurer Brussels, Belgium
Hartmut Goldschmidt Heidelberg, Germany Fredrik Hellem Schjesvold Oslo, Norway
Roman Hajek Ostrava, Czech Republic Tobias Schmidt Slørdahl Trondheim, Norway
Jean-Luc Harousseau Nantes, France Pieter Sonneveld Rotterdam, The Netherlands
Graham Jackson Newcastle upon Tyne, United Kingdom Evangelos Terpos Athens, Greece
Martin Kaiser London, United Kingdom Cyrille Touzeau Nantes, France
Efstathios Kastritis Athens, Greece Carin Uyl Rotterdam, The Netherlands
Shaji Kumar Rochester, USA Niels van de Donk Amsterdam, The Netherlands
Marc Labetoulle Paris, France Marie Von Lilienfeld-Toal Jena, Germany
Xavier Leleu Poitiers, France Josephine M.I. Vos Amsterdam, The Netherlands
Heinz Ludwig Wien, Austria Katja Christina Weisel Hamburg, Germany
Salomon Manier Lille, France Kwee Yong London, United Kingdom
Maria-Victoria Mateos Salamanca, Spain Elena Zamagni Bologna, Italy
Roberto Mina Turin, Italy Sonja Zweegman Amsterdam, The Netherlands
1 Virtual | April 6-9, 2022
3 rd Meeting
European Myeloma Network Meeting
WEDNESDAY, APRIL 6, 2022
14.00.14.15 OPENING CEREMONY 16.45-18.05
AUDITORIUM AGNELLI SESSION IV: BEST ABSTRACTS - ORAL PRESENTATIONS
Chairpersons: A. Broijl, F.H. Schjesvold
14.15-14.45 SESSION I: CLINICAL STUDIES IN PROGRESS
Chairpersons: H. Goldschmidt, T.S. Slørdahl
B01
STROMAL CELL-NEUTROPHIL INTERACTIONS PROMOTE A PRO-TUMOR ENVIRONMENT
New studies under the EMN - F. Gay IN MULTIPLE MYELOMA
National studies and collaborative trials in Europe - C. Touzeau M. de Jong, C. Fokkema, T. van Heusden, N. Papazian, S. Tahri, Z. Kellermayer, P. Vermeulen,
New studies in the USA - S. Kumar M. van Duin, P. van de Woestijne, A. Broijl, P. Sonneveld, T. Cupedo (Rotterdam-NL)
15.00-15.30 SESSION II: PATIENT PERSPECTIVE: PATIENT ASSOCIATION TALK B02
Chairpersons: B.G.M. Durie, H. Scheurer REVERTING THE TUMOR-STROMAL METABOLIC COUPLING BY TARGETING LIPIDS RAFTS
DYNAMICS TO INCREASE SENSITIVITY TO BELANTAMAB MAFODITIN IN MULTIPLE MYELOMA
MPE and patients in Europe - H. Scheurer
A. Romano, E. La Spina, D. Tibullo, C. Giallongo, G. Scandura, A. Barbato, F. Di Raimondo (Catania-IT)
IMF and patients in the USA - B.G.M. Durie
B03
15.45-16.30 SESSION III: EMN-EHA joint session: Access to new treatments SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED
Chairpersons: I. Durand-Zaleski, H. Ludwig
WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Treatment access problems in the evolving treatment landscape: E. Terpos, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, A. Briasoulis, S.Gumeni, P. Malandrakis,
the clinician’s view - J.L. Harousseau E-D. Papanagnou, M. Migkou, N. Kanellias, E. Kastritis, I. P. Trougakos, M. A. Dimopoulos (Athens-GR)
The Atlas initiative and how to improve access for patients - K. Morgan
Health economics & cost-effectiveness: how should drugs be paid for? - C. Uyl
Discussion
2 Virtual | April 6-9, 20223 rd Meeting
European Myeloma Network Meeting
B04 B06
COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH
WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
1B MULTICOHORT STUDY M. Mateos, P. Hari, N. Bahlis, A. Chari, N.W.C.J. van de Donk, B. Dholaria, A.L. Garfall, H. Goldschmidt,
P. Rodriguez-Otero, B. Dholaria, E. Askari, D. Reece, N. van de Donk, A. Chari, H. Goldschmidt, K.M. Kortüm, A. Krishnan, T. Martin, D. Morillo, A. Oriol, D. Reece, C. Rodriguez, P. Rodríguez-Otero,
A. Krishnan, T. Martin, M. Mateos, D. Morillo, C. Rodriguez, L. Rosinol, J. San-Miguel, A. Balari, J.F. San-Miguel, S.Z. Usmani, R. Verona, S.X.W. Lin, T.J. Prior, M. Wade, B. Weiss, J.D. Goldberg, E. Askari
R. Wäsch, K. Weisel, R. Verona, S. Lin, T. Prior, M. Wade, B. Weiss, J. Goldberg, A. Oriol, P. Hari (Salamanca-ES, Milwaukee-USA, Calgary-CA, New York-USA, Amsterdam-NL, Nashville-USA, Philadelphia-USA,
(Navarra-ES, Nashville-USA, Madrid-ES, Toronto-CA, Amsterdam-NL, New York-USA, Heidelberg-DE, Heidelberg-DE, Würzburg-DE, Duarte-USA, San Francisco-USA, Madrid-ES, Badalona-ES, Toronto-CA,
Duarte-USA, San Francisco-USA, Salamanca-ES, Winston-Salem-USA, Barcelona-ES, Freiburg-DE, Winston-Salem-USA, Navarra-ES, Charlotte-USA, Spring House-USA, Raritan-USA)
Hamburg-DE, Spring House-USA, Raritan-USA, Milwaukee-USA)
B07
B05 SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR
RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE
PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
MULTIPLE MYELOMA N.W.C.J. van de Donk, M. Delforge, M. Agha, A.D. Cohen, Y.C. Cohen, J. Hillengass, S. Anguille, T. Kerre,
F. Gay, J.G. Berdeja, V. De Stefano, P. Hari, B. Hooper, A. Haltner, S. Kumar, T. Martin, M.V. Mateos, W. Roeloffzen, J.M. Schecter, K.C. De Braganca, H. Varsos, L. Wang, M. Vogel, E. Zudaire, C. Corsale,
P. Moreau, E. Rosta, I.A. Samjoo, S.Z. Usmani, K. Weisel, C.C. Jackson, Y. Olyslager, J.M. Schecter, M. Akram, D. Geng, T. Nesheiwat, L. Pacaud, P. Sonneveld, S. Zweegman (Amsterdam-NL, Leuven-BE,
M. Vogel, A. Garrett, S. Lee, T. Nesheiwat, L. Pacaud, C. Zhou, S. Valluri, L.J. Costa, Y. Lin Pittsburgh-USA, Philadelphia-USA, Tel Aviv-IL, Buffalo-USA, Edegem-BE, Ghent-BE, Groningen-NL, Raritan -USA,
(Torino, Nashville-USA, Roma, Milwaukee-USA, Sydney-CA, Rochester -USA), San Francisco-USA, Spring House-USA, Piscataway-USA, Rotterdam-NL)
Salamanca-ES, Nantes-FR, Burlington-CA, Charlotte-USA, Hamburg-DE, Raritan-USA, Beerse-BE,
Piscataway-USA, Birmingham-USA) B08
A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN
PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA
E. Terpos, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, A. Briasoulis, S. Gumeni, P. Malandrakis,
E.D. Papanagnou, M. Migkou, N. Kanellias, E. Kastritis, I.P. Trougakos, M.A. Dimopoulos (Athens-GR)
3 Virtual | April 6-9, 20223 rd Meeting
European Myeloma Network Meeting
THURSDAY, APRIL 7, 2022
13.40-14.10 SESSION V: BIOLOGY AUDITO SESSION VI: HOW TO DEFINE HIGH-RISK MYELOMA
16.00-16.50
Chairpersons: N.C. Munshi, N. Raje
ACCORDING TO NEW PROGNOSTIC FACTORS
Chairpersons: J. San Miguel, P. Sonneveld
Genetic evolution:
• From benign to malignant disease - N. Bolli Cytogenetic risk factors: is it time for revision? Detection and impact
• Stromal and immune micro-environment - T. Cupedo of 1q & R2-ISS - M. D’Agostino
• Druggable MM therapeutics: Pathogenetic pathways - E.M. Ocio Emergence of high-risk clones - H. Avet-Loiseau
Circulating tumor cells - B. Paiva
JANSSEN SPONSORED SYMPOSIUM
14.20-15.50 Extramedullary disease - M. Beksac
Considerations for treatment sequencing in multiple myeloma:
Early relapse - K. Yong
a roadmap to cure
BRISTOL MYERS SQUIBB SPONSORED SYMPOSIUM
17.00-18.30
Welcome and introduction - S. Zweegman
Novel immunotherapies for advancing the treatment of multiple myeloma
DITORIUM A Current treatment strategies in patients with multiple myeloma - P. Moreau
Patient case discussion: Welcome and introduction - T. Facon
• Planning the patient journey for a transplant eligible patient Evolving standard of care in NDMM and RRMM - T. Facon
with MM from front-line to fourth-line therapy - S. Zweegman Cellular therapies: a new era of treatment in MM - M.V. Mateos
• Discussion Emerging immune therapies for RRMM: targets and modalities - P. Rodriguez-Otero
• Considerations for a transplant ineligible patient regarding treatment sequencing Emerging preclinical and clinical data for iberdomide and CC-92480 - N. van de Donk
from front-line to fourth-line of therapy in multiple myeloma - R. Mina Discussion
• Discussion
18.40-19.20 SESSION VII: MRD IN MM
Chairpersons: G. Jackson, B. Paiva
MRD in the bone marrow - S. Oliva
MRD in the peripheral blood: mass spec - N. Puig
MRD outside of the bone marrow: imaging - E. Zamagni
How to incorporate MRD in clinical trials? Why, whichand when (again)? - J. San-Miguel
4 Virtual | April 6-9, 20223 rd Meeting
European Myeloma Network Meeting
FRIDAY, APRIL 8, 2022
SESSION VIII: NEWLY DIAGNOSED MM
13.40- 14.40 16.30-17.00 SESSION IX: TREATMENT AT RELAPSE
Chairpersons: R. Hajek, X. Leleu Chairpersons: M. Boccadoro, M.A. Dimopoulos
Transplant-eligible: What to do first - M.V. Mateos
• Which induction therapy: where to aim for and when to switch - P. Moreau How to sequence after first relapse - C. Pawlyn
• Upfront ASCT: does one size fits all? - M. Cavo How to treat triple class refractory myeloma - P. Rodriguez-Otero
• Consolidation and maintenance - P. Sonneveld
• How to treat high risk patients - M. Kaiser SANOFI SPONSORED SYMPOSIUM
17.10-18.40
Non-Transplant-eligible:
Climb every mountain: New routes to tackle in RRMM
• How to treat fit patients - T. Facon DITORIUM A Chairperson: A. Broijl
• How to treat unfit and frail patients - G. Cook
Introduction: State of the art treatment of high-risk patients in RRMM - A. Broijl
Finding the right path: Exploring the nuances of high-risk cytogenetics - A. Broijl
GSK SPONSORED SYMPOSIUM
14.50-16.20
A challenging ascent: The impact of renal impairment - M. Raab
Future treatment and management of heavily pre-treated New peaks to explore: Considerations for frail and elderly patients - S. Manier
and refractory MM patients A changing view? The role of EMD in patients with RRMM - E. Zamagni
Opening remarks: M.V. MateosN Discussion
Future combinations in heavily pre-treated and refractory MM patients - E. Zamagni
Improving patient’s outcome through adverse events management 18.50-19.20 SESSION X: IMMUNETHERAPIES IN MM
Focus on: Early recognition and management of corneal toxicity - M. Labetoulle Chairpersons: H. Einsele, C. Fernández de Larrea
Focus on: Managing neurotoxicity - J. Gallego
CAR-T cell therapies - N. Raje
Focus on: MM management in the context of COVID - M. Von Lilienfeld-Toal
Bispecific antibodies - N. van de Donk
Closing remarks - M.V. Mateos
How to choose & sequence immunetherapy - N.C. Munshi
5 Virtual | April 6-9, 20223 rd Meeting
European Myeloma Network Meeting
SATURDAY, APRIL 9, 2022
9.00-9.30 SESSION XI: AL AMYLOIDOSIS AUDITORIUM AGNELLI 11.00-11.30 SESSION XIII: SIDE EFFECTS MANAGEMENT
Chairpersons: M.C. Minnema, G. Palladini Chairpersons: J. Radocha, L. Rasche
Disease mechanisms & biomarkers - G. Palladini Prophylaxis - M. Delforge
Early diagnosis and optimal treatment - E. Kastritis Covid-19 and myeloma - H. Ludwig
Light chain deposition disease - J.M.I. Vos Bone disease - E. Terpos
9.40-10.00 SESSION XII: WHAT KIND OF TRIALS DO WE NEED IN THE FUTURE? 11.30-11.45 CONCLUSIONS AND FINAL GREETINGS
Chairpersons: R. Mina, K.C. Weisel
Immunetherapy - H. Einsele
Elderly patients - S. Zweegman
10.15-10.45 ADAPTIVE SPONSORED LECTURE
Chairpersons: R. Mina, K.C. Weisel
Assessing Measurable Residual Disease in Multiple Myeloma patients
in Routine Clinical Practice - K. Ramasamy
6 Virtual | April 6-9, 20223 rd Meeting
European Myeloma Network Meeting
POSTER
1. BIOLOGY AND PRECLINICAL 3. RELAPSED/REFRACTORY MULTIPLE MYELOMA
P01 P04
ARGININE STARVATION IN MULTIPLE MYELOMA MICROENVIRONMENT CONVEYS BORTEZOMIB DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND
REFRACTORINESS VIA TLR4 PATHWAY DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL
A. Romano, G. Scandura, C. Giallongo, E. La Spina, A. Barbato, D. Tibullo, F. Di Raimondo (Catania) SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
P. Sonneveld, A. Chanan-Khan, K. Weisel, A.K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder,
2. NEWLY DIAGNOSED MULTIPLE MYELOMA M.V. Mateos, T.M. Mark, M.D. Levin, T. Ahmadi, X. Qin, W. Garvin Mayo, X. Gai, J. Carey, R. Carson, A. Spencer
(Rotterdam-NL, Jacksonville-FL, Hamburg-DE, Atlanta-GA, Budapest, Hungary-H, Ankara-TR, Prague-CS, São Paulo-
P02 BR, Mainz-DE, Salamanca, Spain-E, Aurora-CO, Dordrecht-NL, Plainsboro-NJ, Spring House-PA, Raritan-NJ, Beijing-
PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS RC, Melbourne-AUS)
G. Barilà, L. Bonaldi, A. Martines, A. Pascarella, S. Vedovato, C. Clissa, N. Macrì, A. Bonalumi, L. Pavan, M.
Tinelli, S. Nalio, A. Teramo, G. Calabretto, V.R. Gasparini, M. Krampera, R. Bassan, R. Zambello (Venezia, P05
Padova-IT) DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND
DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL
P03 SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL
RATIONALE AND DEVELOPMENT OF AN E-HEALTH APPLICATION TO DELIVER PATIENT CENTERED M.A. Dimopoulos, A. Oriol, H. Nahi, J. San-Miguel, N.J. Bahlis, S.Z. Usmani, N. Rabin, R.Z. Orlowski, K. Suzuki,
CARE DURING TREATMENT FOR MULTIPLE MYELOMA IN THE NETHERLANDS T. Plesner, S.S. Yoon, D. Ben Yehuda, P.G. Richardson, H. Goldschmidt, D. Reece, T. Ahmadi, X. Qin, W. Garvin
P. Geerts, J. Eijsink, A. Moser, P. ter Horst, C. Boersma, M. Postma (Zwolle-NL, Maastricht-NL, Heerlen-NL, Mayo, X. Gai, J. Carey, R. Carson, P. Moreau (Athens-GR, Barcelona-ES, Stockholm-S, Pamplona-ES, Calgar-AB,
Groningen-NL) New York-USA, London-UK, Houston-TX, Tokyo- J, Vejle-DK, Seoul-ROK, Jerusalem-IL, Boston-MA, Heidelberg-DE,
Toronto-CDN, Plainsboro-NJ, Spring House-PA, Raritan-NJ, Beijing-RC, Nantes-FR)
7 Virtual | April 6-9, 20223 rd Meeting
European Myeloma Network Meeting
P06 P09
UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM
MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY THE AUSTRIAN MYELOMA REGISTRY
MULTIPLE MYELOMA M.A. Benda, H. Ulmer, R. Weger, T. Winder, B. Hartmann, I. Strassl, S. Sormann, E. Willenbacher,
R. Popat, S. Usman, A. Garfall, N. van de Donk, H. Nahi, J. San-Miguel, A. Oriol, A. Nooka, T. Martin, W. Willenbacher (Feldkirch-DE, Triesen-Liechtenstein-A, Innsbruck-A, Linz-A, Graz-A)
L. Rosinol, A. Chari, L. Karlin, L. Benboubker, M. Mateos, N. Bahlis, P. Moreau, B. Besemer, J. Martínez-López,
S. Sidana, L. Pei, D. Trancucci, R. Verona, S. Girgis, Y. Olyslager, M. Jaffe, C. Uhlar, T. Stephenson, P10
R. Van Rampelbergh, A. Banerjee, J. Goldberg, R. Kobos, A. Krishnan (London-UK, Charlotte-USA, TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC
Philadelphia-USA, Amsterdam-NL, Stockholm-SE, Pamplona-ES, Barcelona-ES, Atlanta-USA, San Francisco-USA, ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED
New York-USA, Pierre-Bénite-FR, Tours-FR, Salamanca-ES, Calgary-CA, Nantes-FR, Tuebingen-DE, Madrid-ES, PHASE 1 RESULTS FROM MONUMENTAL-1
Palo Alto-USA, Raritan-USA, Spring House-USA, Antwerp-BE, Duarte-USA) N.W.C.J. van de Donk, M.C. Minnema, J.G. Berdeja, A. Oriol, A. Krishnan, P. Rodríguez-Otero, E. Askari,
M. Mateos, L.J. Costa, R. Verona, J. Ma, S. Girgis, S. Yang, B. W. Hilder, J. Russell, J.D. Goldberg, A. Chari
P07 (Amsterdam-NL, Utrecht-NL, Nashville-USA, Badalona-ES, Duarte-USA, Navarra-ES, Madrid-ES, Salamanca-ES,
RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS Birmingham-USA, Spring House-USA, Raritan-USA, New York-USA)
DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
N.W.C.J. van de Donk, R. Popat, C. Hulin, S. Jagannath, A. Oriol, P.G. Richardson, T. Facon, K. Weisel, P11
J.T. Larsen, M. Minnema, A. Abdallah, A.Z. Badros, S. Knop, E.A. Stadtmauer, M. Chen, T.V. Nguyen, IXAZOMIB WITH CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY
A. Amin, T. Peluso, S. Lonial (Amsterdam-NL, London-UK, Pessac-FR, New York-USA, Badalona-ES, Boston-MA, MYELOMA: MUKEIGHT PHASE II RANDOMISED CONTROLLED TRIAL RESULTS
Lille-FR, Hamburg-DE, Phoenix-AZ, Utrecht-NL, Kansas City-KS, Baltimore-MD, Würzburg-DE, Philadelphia-PA, H. Auner, S. Brown, K. Walker, J. Kendall, B. Dawkins, D. Meads, G. Morgan, M. Kaiser, M. Cook, S. Roberts,
Princeton-NJ, Boudry-CH, Atlanta-GA) C. Parrish, G. Cook (London-UK, Leeds-UK, New York-USA, Birmingham-UK)
P08 P12
CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN– TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RETROSPECTIVE
DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY CHART REVIEW OF REAL-WORLD OUTCOMES FOR STANDARD OF CARE
PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY M.-C. Vekemans, M. Delforge, S. Anguille, J. Depaus, N. Meuleman, A. Van de Velde, I. Vande Broek, D. Strens,
H. Einsele, A.D. Cohen, M. Delforge, J. Hillengass, H. Goldschmidt, K. Weisel, M.-S. Raab, C. Scheid, S. Van Hoorenbeeck, E.J. Moorkens, J. Diels, F. Ghilotti, S. Dalhuisen, S. Vandervennet (Brussels-BE, Leuven-BE,
J.M. Schecter, K.C. De Braganca, H. Varsos, T.-M. Yeh, L. Wang, M. Vogel, C. Corsale, M. Akram, L. Pacaud, Antwerp-BE, Edegem-BE, Yvoir-BE, Lier-BE, Sint-Niklaas-BE, Grimbergen-BE, Beerse-BE, Cologno Monzese, Breda-NL)
T. Nesheiwat, M. Agha, Y.C. Cohen (Würzburg-DE, Philadelphia-USA, Leuven-BE, Buffalo-USA, Heidelberg-DE,
Hamburg-DE, Cologne-DE, Raritan-USA, Piscataway-USA, Pittsburgh-USA, Aviv-IL)
8 Virtual | April 6-9, 20223 rd Meeting
European Myeloma Network Meeting
P13 P17
CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH DARATUMUMAB (D) PLUS LENALIDOMIDE (R) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR
RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? PATIENTS WITH REFRACTORY-RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN
R. Popat, A. Badros, S. Kumar, P. Rodriguez-Otero, A. Cohen, S. Manier, P. Voorhees, F. Gay, R. Rifkin, ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”
T. Martin, A. Chari, K. Weisel, A. Farooq, B. Jeng, W. Chng, H. Lee, J. Berdeja, V. Jadhav, A. Tosolini, G. Mele, N. Cascavilla, N. Di Renzo, A. Guarini, P. Mazza L. Melillo, V. Pavone, G. Tarantini, P. Curci, A.P. Falcone,
L. Eliason, A. Palumbo, M. Dimopoulos, S. Lonial, S. Trudel, P. Richardson, E. Terpos (London-UK, C. Germano, A. Mele, G. Palazzo, G. Palumbo, G. Reddiconto, B. Rossini, G. Specchia, P. Musto, D. Pastore
Baltimore-USA, Rochester-USA, NavarraES, Philadelphia-USA, Lille-FR, Charlotte-USA, Torino, Steamboat (Brindisi, San Giovanni Rotondo, Lecce, Bari, Taranto, Foggia, Tricase, Barletta)
Springs-USA, San Francisco-USA, New York-USA), Hamburg-DE, Chicago-USA, Singapore-J, Houston-USA,
P18
Nashville-US, Bengaluru-IND, Upper Providence-USA, Zug-CH, Athens-GR, Atlanta-USA, Toronto-CDN, Boston-USA)
DARATUMUMAB (D) PLUS BORTEZOMIB (V) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR
P14 PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN
DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”
PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA G. Mele, N. Cascavilla, N. Di Renzo, A. Guarini, P. Mazza, L. Melillo, V. Pavone, G. Tarantini, P. Curci, A.P. Falcone,
S. Usmani, A Alonso, H. Quach, Y. Koh, A. Guenther, CK. Min, X. Leleu, AO. Abdallah, A. Oriol, B. Bessemer, C. Germano, A. Mele, G. Palazzo, G. Palumbo, G. Reddiconto, B. Rossini, G. Specchia, P. Musto, D. Pastore
M. Garg, I Sandhu, K. Weisel, E. Ocio San Miguel, M. Cavo, X. Zhou, M. Kaisermann, L. Mis, D. Williams, (Brindisi, San Giovanni Rotondo, Lecce, Bari, Taranto, Foggia, Tricase, Barletta)
A. Yeakey, G. Ferron-Brady, D. Figueroa, B. Kremer, I. Gupta, W. Janowski (Charlotte-USA, Madrid-ES,
Melbourne-AUS, Seoul-ROK, Schwerin-DE, Poitiers-FR, Kansas City-USA, Badalona-ES, Tübingen-DE, P19
Leicester,-UK, Edmonton-CDN, Hamburg-DE, Santander-ES, Bologna, Waltham-USA, Upper Providence-USA, BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121),
Mississauga-CDN, Research Triangle Park-USA, Newcastle-AUS) A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE
MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL
P15
P. Rodríguez-Otero, N. Shah, N. Munshi, J. Berdeja, S. Jagannath, O. Finney, N. Martin, A. Agarwal, E. Rowe,
EVOLUTION OF MULTIPLE MYELOMA TREATMENT PATTERNS FROM 2015 THROUGH 2019:
T. Campbell, J. San-Miguel (Pamplona-ES, San Francisco-USA, Boston-USA, Nashville-USA, New York-USA,
REAL-WORLD EVIDENCE FROM A EUROPEAN DATABASE STUDY
Cambridge-USA, Princeton-USA)
A. Oriol Rocafiguera T.H. Steinmetz, A. Brescianini, S. Gonzalez-McQuire, N. Eugene, A. Abbasi,
S. Wetten, X. Leleu (Badalona-ES, Barcelona-ES, Cologne-DE, Rotkreuz-CH, Uxbridge-UK, Poitiers-FR) P20
P16 POLYCENTRIC “REAL LIFE” STUDY OF BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY
DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS MULTIPLE MYELOMA
WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY R. Iula, F. Trastulli, R. Della Pepa, A. D’Ambrosio, M. Romano, A. Leone, G. Gaeta, S. Palmieri, S. Rocco,
E. Terpos, I. Ntanasis-Stathopoulos, E. Kastritis, E. Hatjiharissi, E. Katodritou, E. Eleutherakis-Papaiakovou, F. Pane, F. Ferrara, L. Catalano (Napoli)
E. Verrou, M. Gavriatopoulou, A. Leonidakis, S. Delimpasi, P. Malandrakis, M-C. Kyrtsonis, M. Papaioannou,
A. Symeonidis, M.A. Dimopoulos (Athens-GR, Thessaloniki-GR, Patras-GR)
9 Virtual | April 6-9, 20223 rd Meeting
European Myeloma Network Meeting
P21 4. SPECIAL CONDITIONS
SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121)
TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE P25
KARMMA STUDY CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT
P. Rodríguez-Otero, J. San-Miguel, L.D. Anderson Jr, S. Lonial, A. Truppel-Hartmann, J. Sanford, E. Rowe, VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
T.B. Campbell, N. Munshi (Pamplona-ES, Dallas-USA, Atlanta-USA, Cambridge-USA, Princeton-USA, Boston-USA) S. Morè, V.M. Manieri, L. Corvatta, E. Morsia, S. Rupoli, A. Olivieri, M. Offidani (Ancona, Fabriano)
P22 P26
A NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY OF RELAPSED/REFRACTORY EXTRAMEDULLARY MULTIPLE MYELOMA: A MONOCENTRIC RETROSPECTIVE OBSERVATIONAL STUDY
MULTIPLE MYELOMA PATIENTS TREATED WITH IXAZOMIB IN REAL-WORLD SETTINGS IN GREECE; M. Brescini, F. Fazio, M.T. Petrucci (Roma)
INTERIM RESULTS OF THE ‘OL-ORAL’ STUDY
P27
E. Katodritou, M.C. Kyrtsonis, S. Delimpasi, E. Spanoudakis, G. Vassilopoulos, P. Zikos, N. Viniou, G. Kaiafa,
HUMORAL RESPONSE RATE POST MRNA COVID19 VACCINATION (BNT162B2) IS HIGLY DEPENDENT TO
M. Papathanasiou, V. Pappa, E. Michalis, I. Adamopoulos, K. Kokoviadou, G. Tsirakis, C. Poziopoulos,
BONE MARROW PLASMACYTOSIS: LONG FOLLOW-UP OF SYMPTOMATIC MULTIPLE MYELOMA PATIENTS
E. Terpos (Thessaloniki-GR, Athens-GR, Alexandroupoli-GR, Larissa-GR, Patras-GR, Kalamata-GR, Chania-GR)
G. Mele, C. Romano, A. Spina, F. Merchionne, G. Quintana, M. Urbano, A.M. Pasanisi, E. Rinaldi, M.P. Solfrizzi,
P23 A. Romano, G. Guaragna, M.L. DiNoi, A. Miccoli, A. Santoro, D. Pastore (Brindisi)
RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE P28
ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY RESPONSE AND VACCINATION STATUS OR LACK OF IMMUNOPARESIS ARE ASSOCIATED WITH BETTER
F. Fazio, A. Di Rocco, T. Za, V. Tomarchio, A. Rago, A. Piciocchi, T. Caravita di Toritto, O. Annibali, OUTCOME FOLLOWING COVID-19 INFECTION AMONG PATIENTS DIAGNOSED WITH MULTIPLE
V. De Stefano, R. Foà, M. Martelli, M.T. Petrucci (Roma) MYELOMA: A SINGLE CENTER EXPERIENCE ON 110 PATIENTS
G. Cengiz Seval, E. Kircali, D. Koyun, B. Karakaya, H. Yilmaz, G. Yavuz, H. Akbulut, S.K. Toprak, P. Topcuoglu,
P24
O. Arslan, M. Ozcan, O. Ilhan, M. Beksac (Ankara-TR)
EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE
MYELOMA (RRMM) WHO RECEIVE LENALIDOMIDE-SPARING REGIMENS IN EUROPE P29
M. Mateos, X. Leleu, E. Zamagni, M. Delforge, S. Bringhen, A. Broijl, J. de la Rubia, A. Shaw, A. Brescianini, EFFECTS OF VACCINATION ON INCIDENCE AND OUTCOME OF SARS-COV-2 INFECTION IN PATIENTS
S. Gonzalez-McQuire, S. Patel, P. Moreau (Salamanca-ES, Poitiers-FR, Bologna, Leuven-BE, Torino, Rotterdam-NL, WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS)
Valencia-ES, Oxford-UK, Rotkreuz-CH, Uxbridge-UK, Nantes-FR) N. Sgherza, R. Rizzi, P. Curci, D. Roccotelli, M. Croce, M. Avantaggiato, L. Ruga, P. Musto (Bari)
10 Virtual | April 6-9, 20223 rd Meeting
European Myeloma Network Meeting Acknowledgments
PLATINUM SPONSORS
GOLD SPONSORS
SILVER SPONSORS
BRONZE SPONSORS
Virtual | April 6-9, 2022You can also read
